局部晚期胃癌的新辅助化疗的临床观察  

Clinical Observation of Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy

作　　者：肖天林[1] 刘晓洪[1] 方姗姗[1] 杨超[1] 

机构地区：[1]湖北省襄樊市中心医院肿瘤科,襄樊441021

出　　处：《中国医药导刊》2009年第8期1279-1280,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨FOLFOX新辅助化疗方案治疗局部晚期胃癌的近期疗效及毒副反应。方法:35例为病理证实的局部晚期胃癌患者,予FOLFOX化疗方案,治疗2周期后判定疗效及毒副反应。结果:所有接受新辅助化疗的患者临床总有效率(RR)57.2%(20/35),其中完全反应(CR)8.6%(3/35),部分反应(PR)48.6%(17/35),疾病稳定(SD)25.7%(9/35),疾病进展(PD)17.1%(6/35)。手术切除率85.7%(30/35),术后病理水平完全缓解率5.7%(2/35)。主要不良反应为骨髓抑制、胃肠道反应及轻度感觉神经毒性。结论:FOLFOX新辅助化疗方案在局部晚期胃癌的治疗中近期疗效显著,耐受性良好。Objective： To investigate the efficacy and toxicity of the improved FOLFOX regimen as neoadjuvant chemotherapy in the treatment of locally advanced gastric cancer. Methods： Thirty five patients with advanced local gastric cancer diagnosed by the pathology were received improved FOLFOX regimen as neoadjuvant chemotherapy. The efficacy and toxicity were evaluated after 2 courses. Results： The total response rates （CR＋PR） were 57.2%（20/35）, CR8.6%（3/35）, PR48.6%（17/35）, SD25.7%（9/35）, PD17.1%（6/35）.The radical operation rate was 85.7%（30/35）. Complete pathological response rate was 5.7%（2/35）. The most common toxicities included leukocytopenia, nausea, vomiting and mild peripheral neurotoxicity. Conclusion： The improved FOLFOX regimen may be an effective and well-tolerated regimen as neoadjuvant chemotherapy for locally advanced gastric cancer.

关 键 词：胃癌 新辅助化疗 疗效 毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]